Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy AVEO Pharmaceuticals stock in Canada | $7.3
Own AVEO Pharmaceuticals shares in just a few minutes.
AVEO Pharmaceuticals is a biotechnology business based in the US. AVEO Pharmaceuticals stocks (AVEO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.3 – an increase of 7.67% over the previous week. AVEO Pharmaceuticals employs 49 staff and has a trailing 12-month revenue of around $7.2 million.
How to buy AVEO Pharmaceuticals stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AVEO in this case.
- Research AVEO Pharmaceuticals stocks. The platform should provide the latest information available.
- Buy your AVEO Pharmaceuticals stocks. It's that simple.
What's in this guide?
- Can I buy shares in AVEO Pharmaceuticals?
- Has coronavirus impacted AVEO Pharmaceuticals shares?
- AVEO Pharmaceuticals shares summary
- Compare share dealing platforms
- Is AVEO Pharmaceuticals stock a buy or sell?
- AVEO Pharmaceuticals performance over time
- Can I short AVEO Pharmaceuticals shares?
- AVEO Pharmaceuticals's financials
- How volatile are AVEO Pharmaceuticals shares?
- Does AVEO Pharmaceuticals pay a dividend?
- Have AVEO Pharmaceuticals shares ever split?
- Other common questions
How has Coronavirus impacted AVEO Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, AVEO Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $7.3, which is 27.12% up on its pre-crash value of $5.32 and 1,408.26% up on the lowest point reached during the March crash when the stocks fell as low as $0.484.
If you had bought $1,000 worth of AVEO Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $5,117.20 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $14,257.85.
AVEO Pharmaceuticals stock priceUse our graph to track the performance of AVEO stocks over time.
AVEO Pharmaceuticals stocks at a glance
|Latest market close||$7.3|
|52-week range||$4.13 - $13.21|
|50-day moving average||$6.4606|
|200-day moving average||$7.5426|
|Wall St. target price||$22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.028|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy AVEO Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
AVEO Pharmaceuticals price performance over time
|1 month (2021-06-25)||4.29%|
|3 months (2021-04-26)||2.38%|
AVEO Pharmaceuticals financials
|Revenue TTM||USD$7.2 million|
|Gross profit TTM||USD$-16,660,000|
|Return on assets TTM||-35.6%|
|Return on equity TTM||-124.16%|
|Market capitalisation||USD$181.1 million|
TTM: trailing 12 months
How to short and sell AVEO Pharmaceuticals stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "AVEO.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 1.9 million AVEO Pharmaceuticals stocks held short by investors – that's known as AVEO Pharmaceuticals's "short interest". This figure is 21.6% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting AVEO Pharmaceuticals stocks can be evaluated.
AVEO Pharmaceuticals's "short interest ratio" (SIR)
AVEO Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AVEO Pharmaceuticals stocks currently shorted divided by the average quantity of AVEO Pharmaceuticals stocks traded daily (recently around 565157.14285714). AVEO Pharmaceuticals's SIR currently stands at 3.36. In other words for every 100,000 AVEO Pharmaceuticals stocks traded daily on the market, roughly 3360 stocks are currently held short.
However AVEO Pharmaceuticals's short interest can also be evaluated against the total number of AVEO Pharmaceuticals stocks, or, against the total number of tradable AVEO Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVEO Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 AVEO Pharmaceuticals stocks in existence, roughly 60 stocks are currently held short) or 0.0626% of the tradable stocks (for every 100,000 tradable AVEO Pharmaceuticals stocks, roughly 63 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against AVEO Pharmaceuticals.
Find out more about how you can short AVEO Pharmaceuticals stock.
AVEO Pharmaceuticals stock dividends
We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Have AVEO Pharmaceuticals stocks ever split?
AVEO Pharmaceuticals stocks were split on a 1:10 basis on 20 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for AVEO Pharmaceuticals stocks which in turn could have impacted AVEO Pharmaceuticals's stock price.
AVEO Pharmaceuticals stock price volatility
Over the last 12 months, AVEO Pharmaceuticals's stocks have ranged in value from as little as $4.13 up to $13.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 1.2035. This would suggest that AVEO Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Stocks similar to AVEO Pharmaceuticals
AVEO Pharmaceuticals in the news
AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Aveo Pharmaceuticals to hold a key opinion leader webinar
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
Frequently asked questions
More guides on Finder
How to buy Allied Esports Entertainment stock in Canada | $2.32
Steps to owning and managing AESE with 24-hour and historical pricing before you buy.
How to buy Genfit stock in Canada | $4
Steps to owning and managing GNFT with 24-hour and historical pricing before you buy.
How to buy Summit Midstream Partners stock in Canada | $25.24
Steps to owning and managing SMLP with 24-hour and historical pricing before you buy.
How to buy 1Life Healthcare stock in Canada | $37
Steps to owning and managing ONEM with 24-hour and historical pricing before you buy.
How to buy TScan Therapeutics (TCRX) stock in Canada when it goes public
Everything we know about the TScan Therapeutics IPO, plus information on how to buy in.
How to buy Sight Sciences (SGHT) stock in Canada when it goes public
Everything we know about the Sight Sciences IPO, plus information on how to buy in.
How to buy Sera Prognostics (SERA) stock in Canada when it goes public
Everything we know about the Sera Prognostics IPO, plus information on how to buy in.
How to buy Rapid Micro Biosystems (RPID) stock in Canada when it goes public
Everything we know about the Rapid Micro Biosystems IPO, plus information on how to buy in.
How to buy Perspectum Group (SCAN) stock in Canada when it goes public
Everything we know about the Perspectum Group IPO, plus information on how to buy in.
How to buy Imago BioSciences (IMGO) stock in Canada when it goes public
Everything we know about the Imago BioSciences IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.